Endoscopic variceal ligation plus nadolol and sucralfate compared with ligation alone for the prevention of variceal rebleeding: a prospective, randomized trial - PubMed (original) (raw)
Clinical Trial
Endoscopic variceal ligation plus nadolol and sucralfate compared with ligation alone for the prevention of variceal rebleeding: a prospective, randomized trial
G H Lo et al. Hepatology. 2000 Sep.
Abstract
Both beta-blockers and endoscopic variceal ligation (EVL) have proven to be valuable alternatives to sclerotherapy in the prevention of variceal rebleeding. Sucralfate is a mucosal protector. The effects of combinations of beta-blocker, band ligation, and sucralfate (triple therapy) remain unknown. A total of 122 patients with a history of esophageal variceal bleeding were randomized to receive EVL only (group A, 62 patients) or triple therapy (group B, 60 patients). The procedure for the triple therapy included ligation with the addition of sucralfate granules until variceal obliteration. In addition, nadolol was administered during the course of the study or until death. After a median follow-up of 21 months, recurrent upper gastrointestinal bleeding developed in 29 patients (47%) in group A and 14 patients (23%) in group B (P =.005). Recurrent bleeding from esophagogastric varices occurred in 18 patients in group A and 7 patients in group B (P =.001). Twenty-one patients in group A (50%) and 12 patients (26%) in group B experienced variceal recurrence after variceal obliteration (P <.05). Treatment failure occurred in 11 patients (18%) in group A and in 4 patients (7%) in group B (P =.05). Twenty patients from group A and 10 patients from group B died (P =.08); 9 and 4 of these deaths, respectively, were attributed to variceal hemorrhage (P =.26). The combination of ligation, nadolol, and sucralfate (triple therapy) proved more effective than banding ligation alone in terms of prevention of variceal recurrence and upper gastrointestinal rebleeding as well as variceal rebleeding.
Comment in
- Prevention of variceal rebleeding: endoscopes, drugs, and more.
Bosch J. Bosch J. Hepatology. 2000 Sep;32(3):660-2. doi: 10.1053/jhep.2000.16663. Hepatology. 2000. PMID: 10960465 Review. No abstract available.
Similar articles
- Variceal ligation plus nadolol compared with ligation for prophylaxis of variceal rebleeding: a multicenter trial.
de la Peña J, Brullet E, Sanchez-Hernández E, Rivero M, Vergara M, Martin-Lorente JL, Garcia Suárez C. de la Peña J, et al. Hepatology. 2005 Mar;41(3):572-8. doi: 10.1002/hep.20584. Hepatology. 2005. PMID: 15726659 Clinical Trial. - Prospective multicenter randomized trial comparing banding ligation with sclerotherapy of esophageal varices.
Masci E, Stigliano R, Mariani A, Bertoni G, Baroncini D, Cennamo V, Micheletti G, Casetti T, Tansini P, Buscarini E, Ranzato R, Norberto L. Masci E, et al. Hepatogastroenterology. 1999 May-Jun;46(27):1769-73. Hepatogastroenterology. 1999. PMID: 10430341 Clinical Trial. - [Nadolol as an adjuvant to sclerotherapy of esophageal varices for prevention of recurrent hemorrhaging].
Villanueva C, Martínez FJ, Torras X, Sáinz S, Soriano G, González D, Balanzó J. Villanueva C, et al. Rev Esp Enferm Dig. 1994 Jul;86(1):499-504. Rev Esp Enferm Dig. 1994. PMID: 7917561 Clinical Trial. Spanish. - The role of endoscopy in secondary prophylaxis of esophageal varices.
Lo GH. Lo GH. Clin Liver Dis. 2010 May;14(2):307-23. doi: 10.1016/j.cld.2010.03.009. Clin Liver Dis. 2010. PMID: 20682237 Review. - Prevention of variceal rebleeding.
Burroughs AK, McCormick PA. Burroughs AK, et al. Gastroenterol Clin North Am. 1992 Mar;21(1):119-47. Gastroenterol Clin North Am. 1992. PMID: 1349003 Review.
Cited by
- Non-selective beta-blockers and the incidence of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis.
He X, Zhao Z, Jiang X, Sun Y. He X, et al. Front Pharmacol. 2023 Jul 19;14:1216059. doi: 10.3389/fphar.2023.1216059. eCollection 2023. Front Pharmacol. 2023. PMID: 37538177 Free PMC article. - Clinical algorithms for the prevention of variceal bleeding and rebleeding in patients with liver cirrhosis.
Pfisterer N, Unger LW, Reiberger T. Pfisterer N, et al. World J Hepatol. 2021 Jul 27;13(7):731-746. doi: 10.4254/wjh.v13.i7.731. World J Hepatol. 2021. PMID: 34367495 Free PMC article. Review. - Evidence-based clinical practice guidelines for Liver Cirrhosis 2020.
Yoshiji H, Nagoshi S, Akahane T, Asaoka Y, Ueno Y, Ogawa K, Kawaguchi T, Kurosaki M, Sakaida I, Shimizu M, Taniai M, Terai S, Nishikawa H, Hiasa Y, Hidaka H, Miwa H, Chayama K, Enomoto N, Shimosegawa T, Takehara T, Koike K. Yoshiji H, et al. J Gastroenterol. 2021 Jul;56(7):593-619. doi: 10.1007/s00535-021-01788-x. Epub 2021 Jul 7. J Gastroenterol. 2021. PMID: 34231046 Free PMC article. Review. - Secondary prevention of variceal bleeding in adults with previous oesophageal variceal bleeding due to decompensated liver cirrhosis: a network meta-analysis.
Plaz Torres MC, Best LM, Freeman SC, Roberts D, Cooper NJ, Sutton AJ, Roccarina D, Benmassaoud A, Iogna Prat L, Williams NR, Csenar M, Fritche D, Begum T, Arunan S, Tapp M, Milne EJ, Pavlov CS, Davidson BR, Tsochatzis E, Gurusamy KS. Plaz Torres MC, et al. Cochrane Database Syst Rev. 2021 Mar 30;3(3):CD013122. doi: 10.1002/14651858.CD013122.pub2. Cochrane Database Syst Rev. 2021. PMID: 33784794 Free PMC article. - KASL clinical practice guidelines for liver cirrhosis: Varices, hepatic encephalopathy, and related complications.
Korean Association for the Study of the Liver (KASL). Korean Association for the Study of the Liver (KASL). Clin Mol Hepatol. 2020 Apr;26(2):83-127. doi: 10.3350/cmh.2019.0010n. Epub 2020 Jan 10. Clin Mol Hepatol. 2020. PMID: 31918536 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical